Guardant Health and Flatiron Health announced a strategic collaboration to build a proprietary, cloud-based information platform integrating liquid biopsy-based genomic testing with clinical treatment and outcomes data to support the accelerated development of targeted therapies for cancer.
The collaboration combines advanced clinical insights from the FlatironHealthOncologyCloudTM platform with genomic data from Guardant Health’s Guardant360 liquid biopsy platform. The new platform will enable life science companies to uncover new molecular targets, expand clinical indications, reduce the time to recruit and select patients for trials, and longitudinally follow patients and their progress over time.
"Integrating clinical and genomic information has the potential to dramatically improve cancer treatment and advance therapy development," said Nat Turner, co-founder and chief executive officer, Flatiron Health. "Flatiron Health and Guardant Health’s collective technology, oncology know-how and genomic expertise will deliver an advanced, cloud-based platform to enhance patient care."
Guardant Health and Flatiron Health will work together to develop products that integrate anonymous clinical treatment and outcomes data with genomic data for patients who have undergone testing with Guardant360.
The HIPAA-compliant information platform will be available to life science companies in the first half of 2016.
"Today, oncologists and patients are demanding new therapies matched to their underlying tumor genomics to improve cancer treatment," said Guardant Health CEO and co-founder Helmy Eltoukhy.
"Guardant360 removes the tissue barrier to accessing this genomic information in real-time. When combined with Flatiron Health’s clinical data, this will significantly accelerate timelines for drug development, enabling many new treatment options for millions of cancer patients."